These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 23.05.2020 and posted on 26.05.2020by Nischal Komal Karki, Niraj Verma, Francesco Trozzi, Peng Tao, Elfi Kraka, Brian Zoltowski
Severe Acute Respiratory Syndrome Corona Virus 2 has altered life on a global scale. Currently, research labs around the world are looking for new pharmaceutical treatments by repurposing existing drugs, identifying potential antibody-based therapeutics, as well as the design of new pharmaceutical products and vaccines. To be able to rapidly identify potentional new treatments we require global cooperation and an enhanced open-access research model to distribute new ideas and leads. Herein, we employ a combined machine learning and drug docking approach to evaluate the potential efficacy of existing FDA and World approved drugs to impact the ACE2-Spike complex necessary for viral entry and replication. Further, we extend the machine learning approach to databases containing between 700,000-1 billion compounds. The results of large library screens are incorporated into a open-access web interface to allow researchers from diverse fields to target molecules of interest. Our combined approach allows for both the identification of existing drugs that may be able to be repurposed, and de novo design of ACE2-regulatory compounds. Through these efforts we identify intriguing links between COVID-19 pathologies, particularly in regard to possible sex-differences in disease outcomes.